Abstract
Managing psoriasis in the elderly can be difficult for physicians, who must consider comorbidities, the resulting polypharmacy, and progressive functional impairment of several organs. Indeed, topical agents are the first-line treatment for limited disease. Phototherapy is recommended if topical drugs are not sufficient and the patient has multiple comorbidities and risk factors that make them a poor candidate for an oral or injectable systemic agent. The most important pharmacokinetic alteration in the elderly population is the decreased excretory capacity of the kidney; thus, cyclosporine should be considered a last resort treatment, and the administered dose of methotrexate should be lowered according to the reduction in estimated creatinine clearance. Acitretin can be used in the absence of severe renal insufficiency, paying attention to lipid profile, treating eventual hyperlipidemia, and closely monitoring liver enzymes. Available data on biological drugs in the elderly are limited. Biologics are associated with a small but significant overall risk of infections. However, there is no convincing evidence that the relative risk of infection with anti-tumor necrosis factor (TNF)-α therapy increases with age. Nevertheless, the package inserts for biologics recommend caution when administering these medications to the geriatric population, due to the high baseline risk of infection in such patients. Etanercept seems to be well tolerated, possibly because of its lower immunosuppressive characteristics compared with other biologics. However, studies with larger sample sizes are needed to confirm its safety.
Similar content being viewed by others
References
Ayala F. Clinical presentation of psoriasis. Reumatismo. 2007;59:40–5.
Henseler T, Christophers E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol. 1985;13:450–6.
Mrowietz U, Kragballe K, Reich K, Spuls P, Griffiths CE, Nast A, Franke J, Antoniou C, Arenberger P, Balieva F, Bylaite M, Correia O, Daudén E, Gisondi P, Iversen L, Kemény L, Lahfa M, Nijsten T, Rantanen T, Reich A, Rosenbach T, Segaert S, Smith C, Talme T, Volc-Platzer B, Yawalkar N. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303:1–10.
Wong JW, Koo JY. The safety of systemic treatments that can be used for geriatric psoriasis patients: a review. Dermatol Res Pract. 2012;2012:367475.
Yosipovitch G, Tang MB. Practical management of psoriasis in the elderly: epidemiology, clinical aspects, quality of life, patient education and treatment options. Drugs Aging. 2002;19:847–63.
Shekelle PG, Woolf SH, Eccles M, Grimshaw J. Clinical guidelines: developing guidelines. BMJ. 1999;318:593–6.
Parslew R, Traulsen J. Efficacy and local safety of a calcipotriol/betamethasone dipropionate ointment in elderly patients with psoriasis vulgaris. Eur J Dermatol. 2005;15:37–9.
Kaufmann R, Bibby AJ, Bissonnette R, Cambazard F, Chu AC, Decroix J, Douglas WS, Lowson D, Mascaro JM, Murphy GM, Stymne B. A new calcipotriol/betamethasone dipropionate formulation (Daivobet) is an effective once-daily treatment for psoriasis vulgaris. Dermatology. 2002;205:389–93.
Tirado-Sánchez A, Ponce-Olivera RM. Preliminary study of the efficacy and tolerability of combination therapy with calcipotriene ointment 0.005% and tacrolimus ointment 0.1% in the treatment of stable plaque psoriasis. Cutis. 2012;90:140–4.
Grozdev IS, Van Voorhees AS, Gottlieb AB, Hsu S, Lebwohl MG, Bebo BF Jr, Korman NJ. Psoriasis in the elderly: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2011;65:537–45.
Osmancevic A, Landin-Wilhelmsen K, Larkö O, Mellström D, Wennberg AM, Hulthén L, Krogstad AL. UVB therapy increases 25(OH) vitamin D syntheses in postmenopausal women with psoriasis. Photodermatol Photoimmunol Photomed. 2007;23:172–8.
Fairris GM, Dewhurst AG, White JE, Campbell MJ. Methotrexate dosage in patients aged over 50 with psoriasis. BMJ. 1989;298:801–2.
Collins P, Rogers S. The efficacy of methotrexate in psoriasis—a review of 40 cases. Clin Exp Dermatol. 1992;17:257–60.
Adalimumab [package insert], North Chicago; 2002. http://www.accessdata.fda.gov/drugsatfdadocs/label/2002/adalabb123102LB.htm.
Infliximab [package insert], Janssen, Toronto; 2010. http://www.remicade.com/remicade/assets/HCPPPI.pdf.
Ustekinumab [package insert], Janssen Biotech, Horsham; 2011. http://www.drugs.com/pro/stelara.html.
Etanercept [package insert], Amgen, Thousand Oaks; 1998–2011. http://pi.amgen.com/unitedstates/enbrel/derm/enbrelpi.pdf.
Militello G, Xia A, Stevens SR, Van Voorhees AS. Etanercept for the treatment of psoriasis in the elderly. J Am Acad Dermatol. 2006;55:517–9.
Menter A, Gordon KB, Leonardi CL, Gu Y, Goldblum OM. Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis. J Am Acad Dermatol. 2010;63:448–56.
Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Fu B, Ustianowski AP, Watson KD, Lunt M, Symmons DP. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology. 2011;50:124–31.
Fleischmann R, Baumgartner SW, Weisman MH, Liu T, White B, Peloso P. Long term safety of etanercept in elderly subjects with rheumatic diseases. Ann Rheum Dis. 2006;65:379–84.
Flamminger A, Maibach H. Drug dosage in the elderly: dermatological drugs. Drugs Aging. 2006;23:203–15.
Nadai M, Katoh M. Changes in pharmacokinetics in elderly patients. Nihon Rinsho. 2013;71(6):999–1003.
Gisondi P, Girolomoni G, Sampogna F, Tabolli S, Abeni D. Prevalence of psoriatic arthritis and joint complaints in a large population of Italian patients hospitalized for psoriasis. Eur J Dermatol. 2005;15:279–83.
Gelfand JM, Gladman DD, Mease PJ, Smith N, Margolis DJ, Nijsten T, Stern RS, Feldman SR, Rolstad T. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol. 2005;53:573.
Kimball AB, Jacobson C, Weiss S, Vreeland MG, Wu Y. The psychosocial burden of psoriasis. Am J Clin Dermatol. 2005;6:383–92.
Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol. 1995;32:982–6.
Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol. 2006;55:829–35.
Mallbris L, Ritchlin CT, Stahle M. Metabolic disorders in patients with psoriasis and psoriatic arthritis. Curr Rheumatol Rep. 2006;8:355–63.
Mallbris L, Akre O, Granath F, Yin L, Lindelöf B, Ekbom A, Ståhle-Bäckdahl M. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol. 2004;19:225–30.
Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. J Am Acad Dermatol. 2006;296:1735–41.
Wakkee M, Thio HB, Prens EP, Sijbrands EJ, Neumann HA. Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients. Atherosclerosis. 2007;190:1–9.
Wick G, Jansen-Dürr P, Berger P, Blasko I, Grubeck-Loebenstein B. Diseases of aging. Vaccine. 2000;18:1567–83.
Meyer KC. Aging. Proc Am Thorac Soc. 2005;2:433–9.
Leonardi C, Strober B, Gottlieb AB, Elewski BE, Ortonne JP, van de Kerkhof P, Chiou CF, Dunn M, Jahreis A. Long-term safety and efficacy of etanercept in patients with psoriasis: an open-label study. J Drugs Dermatol. 2010;9:928–37.
Funding sources
None declared.
Conflict of interest
N. Balato, C. Patruno, M. Napolitano, A. Patrì, F. Ayala and R. Scarpa declare no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Balato, N., Patruno, C., Napolitano, M. et al. Managing Moderate-to-Severe Psoriasis in the Elderly. Drugs Aging 31, 233–238 (2014). https://doi.org/10.1007/s40266-014-0156-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40266-014-0156-6